Trump's FDA nominee Heidi Overton could bring renewed scrutiny to mifepristone, says Americans United for Life CEO who calls her a "pro-life" pick.
<iframe src="https://statesidedaily.com/embed/cluster/c02bed0d5ee940daa4911e3d3c4c316f17fc015a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Pro-life CEO predicts Trump FDA nominee could bring renewed scrutiny to abortion drug risks"></iframe>
Trump's FDA nominee Heidi Overton could bring renewed scrutiny to mifepristone, says Americans United for Life CEO who calls her a "pro-life" pick.
